LG CNS expands AI transformation push into pharma, biotech

LG CNS, an IT services and digital transformation arm of LG Group, is expanding its artificial intelligence (AI) business into the pharmaceutical and biotechnology sector, securing a large-scale contract for a government-led drug R&D initiative and deploying an automated quality assessment system for pharmaceutical products. The company announced Wednesday that it is participating in the Ministry of Health and Welfare’s AI-driven drug R&D program, which will invest about 37.1 billion won ($25.2 million) over four years and three months. In this project, LG CNS will lead in developing an AI-powered platform to design and support clinical trials for new drug research. It will also build an integrated management framework that will utilize agentic AI to orchestrate various AI models that other participating institutions developed, creating synergies across the ecosystem. The company will apply a decentralized machine learning approach known as federated learning to the platform, enabling hospitals and clinical research centers to jointly train AI models without sharing sensitive data extWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times